Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy individualization.

Gareth J Veal1, Sally A Coulthard, Alan V Boddy

  • 1Northern Institute for Cancer Research, Cancer Research Unit, Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, NE2 4HH, United Kingdom. G.J.Veal@ncl.ac.uk

Investigational New Drugs
|August 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

Ear and hearing·2026
Same author

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Drug delivery·2026
Same author

Retinal organoid screening reveals ABT-737 and luminespib as potential agents against a cone- precursor-derived subtype of retinoblastoma.

Molecular therapy. Oncology·2026
Same author

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

British journal of clinical pharmacology·2026
Same author

Development and validation of an LC-MS/MS method for the quantification of novel therapeutic TT-478, a selective adenosine receptor 2B antagonist, for a phase I/II clinical trial.

Bioanalysis·2025
Same author

Understanding the Potential Importance of Pharmacokinetic Variability in the Setting of ALL.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Individualizing chemotherapy dosing using patient characteristics like renal function and pharmacogenetics can improve treatment outcomes. This approach aims for targeted drug exposure, reducing side effects and enhancing efficacy for better cancer patient care.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Standard chemotherapy dosing based on body size results in significant interpatient variability in treatment response and side effects.
  • This variation can lead to treatment failure or unacceptable toxicity in some cancer patients.

Purpose of the Study:

  • To review approaches for individualizing chemotherapy drug dosing.
  • To provide examples of applying these methods and discuss future pharmacogenetic contributions to dose optimization.

Main Methods:

  • Review of recent studies on rational drug dosing strategies.
  • Incorporation of patient-specific factors: renal function, pharmacogenetics, and drug metabolism.
  • Integration of therapeutic drug monitoring and adaptive dosing.

Related Experiment Videos

Main Results:

  • Personalized dosing strategies can achieve targeted systemic drug exposure.
  • This can lead to more consistent clinical outcomes in patients receiving chemotherapy.

Conclusions:

  • Individualized chemotherapy dosing holds potential for optimizing the use of current anticancer agents.
  • Advances in pharmacogenetics are expected to further refine dose optimization for improved cancer treatment.